title: Ventricular repolarization time indexes following anthracycline treatment.
abstract: The anthracyclines, doxorubicin and daunorubicin, are antibiotics effective in the treatment of many malignancies. However, their usefulness is limited by the development of potentially fatal cardiotoxicity. Cardiac monitoring by a noninvasive test capable of identifying patients at high risk of cardiac damage, before the ejection fraction deteriorates would have clinical utility. Electrocardiograms and echocardiograms are routinely utilized for noninvasive assessment of myocardial function. However, of the ECG abnormalities described, none has been noted to be of consistent predictive value for cardiotoxicity. The aim of this study was to assess the effects of doxorubicin on ventricular repolarization time indexes, as they have been shown to be effective in the identification of electrical myocardial instability and, hence, in the identification of risk for either arrhythmia or heart failure. For this reason, electrocardiograms were compared in 35 cancer patients at the first presentation (drug-free state) and after 29.4 +/- 37.65 weeks of treatment with doxorubicin. The results of the present study showed that after only a short period of treatment with doxorubicin there was a significant increase in ventricular recovery time dispersion indexes (QTc, JT, and JTc dispersion, and their "adjusted" values). Thus, increased regional variation in ventricular repolarization could be, in the absence of a significant modification of the echocardiographic parameters, an early marker of an electropathy, due to the early cardiotoxic action of doxorubicin on myocardial cells, eventually leading to heart failure.
authors.affiliation: Seconda Università degli Studi di Napoli Istituto Medico-Chirurgico di Cardiologia, Cattedra di Cardiologia, Napoli, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Sarubbi
authors.forename: M
authors.initials: M
authors.lastname: Orditura
authors.forename: V
authors.initials: V
authors.lastname: Ducceschi
authors.forename: F
authors.initials: F
authors.lastname: De Vita
authors.forename: L
authors.initials: L
authors.lastname: Santangelo
authors.forename: F
authors.initials: F
authors.lastname: Ciaramella
authors.forename: G
authors.initials: G
authors.lastname: Catalano
authors.forename: A
authors.initials: A
authors.lastname: Iacono
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000009:adverse effects*; D004452:Echocardiography; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000503:physiopathology; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D012189:Retrospective Studies; D013318:Stroke Volume / Q000187:drug effects; D013964:Thyroid Neoplasms / Q000188:drug therapy
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin